Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Drug Profile

Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Alternative Names: AFM 12; AFM 18; AFM 20; AFM 21; AFM 22; AFM 24; AFM 24+; AFM 26; AFM 26+; anti CD19 x anti CD16; anti CD33 X anti CD3; anti-EGFRvIII/CD16A Tand AB; anti-EGFRvIII/CD3 TandAb; anti-EpCAM TandAb; Antibody-based non-Hodgkin's lymphoma therapeutics - Affimed; MHC-peptide complex antibody - Affimed; Trispecific Abs

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Amphivena Therapeutics
  • Class Bispecific antibodies; Monoclonal antibodies; Trispecific antibodies
  • Mechanism of Action Apoptosis stimulants; B-cell maturation antigen modulators; CD19 antigen modulators; CD200 antigen modulators; CD3 antigen modulators; CD33 antigen modulators; Epidermal growth factor receptor antagonists; Epithelial cell adhesion molecule inhibitors; Fc gamma receptor IIIA modulators; Immunomodulators; Major histocompatibility complex inhibitors; Matrix metalloproteinase 1 inhibitors; Natural killer cell stimulants; T lymphocyte stimulants; T-lymphocyte differentiation antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 27 Jun 2017 Updated pharmacodynamics data from a preclinical study in Cancer released by Affimed
  • 05 Jun 2017 Pharmacodynamics data from a preclinical programme in Multiple myeloma presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 05 Apr 2017 Adverse events and pharmacodynamics data from a preclinical studies in Cancer presented at the (108th Annual meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top